The skeleton: A multi-functional complex organ. New insights into osteoblasts and their role in bone formation: The central role of PI3Kinase

Journal of Endocrinology

Volumn 211, Issue 2, 2011, Pages 123-130

  Guntur, Anyonya R ^a   Rosen, Clifford J ^a  

^a Maine Medical Center Research Institute   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; GLUCOSE; OSTEOCALCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2;

BONE DEVELOPMENT; BONE REMODELING; BONE TURNOVER; GENETIC ENGINEERING; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; REVIEW; SKELETON;

ANIMALS; BONE AND BONES; CARTILAGE; HUMANS; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOGENESIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 83455211711     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-11-0175     Document Type: Review

References (68)

1. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese CB & Cohen P 1997 Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B[alpha]. Current Biology 7 261-269.
2. Almeida M, Han L, Martin-Millan M, O'Brien CA & Manolagas SC 2007 Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting β-catenin from T cell factor- to Forkhead box O-mediated transcription. Journal of Biological Chemistry 282 27298-27305.
3. Alvarez-Garcia O, Carbajo-Pérez E, Garcia E, Gil H, Molinos I, Rodriguez J, Ordoñez F & Santos F 2007 Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatric Nephrology 22 954-961.
4. Ambrogini E, Maria A, Marta M-M, Ji-Hye P, Ronald AD & Li H 2010 FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metabolism 11 136-146.
5. Baron R & Rawadi G 2007 Targeting the Wnt/{beta}-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148 2635-2643.
6. Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N, Wu H, Yu K, Ornitz DM, Olson EN et al. 2004 A twist code determines the onset of osteoblast differentiation. Developmental Cell 6 423-435.
7. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J & Greenberg ME 1999 Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 857-868.
8. Cantley LC 2002 The phosphoinositide 3-kinase pathway. Science 296 1655-1657.
9. Clemens TL & Karsenty G 2011 The osteoblast: an insulin target cell controlling glucose homeostasis. Journal of Bone and Mineral Research 26 677-680.
10. Day TF, Guo X, Garrett-Beal L & Yang Y 2005 Wnt/2-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Developmental Cell 8 739-750.
11. DeMambro VE, Clemmons DR, Horton LG, Bouxsein ML, Wood TL, Beamer WG, Canalis E & Rosen CJ 2008 Gender-specific changes in bone turnover and skeletal architecture in Igfbp-2-null mice. Endocrinology 149 2051-2061.
12. Ducy P, Zhang R, Geoffroy V, Ridall AL & Karsenty G 1997 Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89 747-754.
13. FerronM, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P & Karsenty G 2010 Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142 296-308.
14. Fingar DC & Blenis J 2004 Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23 3151-3171.
15. Ford-Hutchinson AF, Ali Z, Lines SE, Hallgrímsson B, Boyd SK & Jirik FR 2007 Inactivation of Pten in osteo-chondroprogenitor cells leads to epiphyseal growth plate abnormalities and skeletal overgrowth. Journal of Bone and Mineral Research 22 1245-1259.
16. Franke TF, Kaplan DR & Cantley LC 1997 PI3K: downstream AKTion blocks apoptosis. Cell 88 435-437.
17. Fujita T, Azuma Y, Fukuyama R, Hattori Y, Yoshida C, Koida M, Ogita K & Komori T 2004 Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. Journal of Cell Biology 166 85-95.
18. Ghosh-Choudhury N, Abboud SL, Nishimura R, Celeste A, Mahimainathan L & Choudhury GG 2002 Requirement of BMP-2-induced phosphatidylinositol 3-kinase and Akt serine/threonine kinase in osteoblast differentiation and Smad-dependent BMP-2 gene transcription. Journal of Biological Chemistry 277 33361-33368.
19. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA & Marriott TB 2007 Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Annals of Internal Medicine 146 W326-W380.
20. Guntur AR, Reinhold MI, Cuellar J & Naski MC 2011 Conditional ablation of Pten in osteoprogenitors stimulates FGF signaling. Development 138 1433-1444.
21. Hallgrímsson B, Lieberman DE, Liu W, Ford-Hutchinson AF & Jirik FR 2007 Epigenetic interactions and the structure of phenotypic variation in the cranium. Evolution and Development 9 76-91.
22. Hill R & Wu H 2009 PTEN, stem cells, and cancer stem cells. Journal of Biological Chemistry 284 11755-11759.
23. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere M-C, Bouxsein ML, Deng L, Clemens TL & Williams BO 2005 Essential role of b-catenin in postnatal bone acquisition. Journal of Biological Chemistry 280 21162-21168.
24. Hsieh S-C, Chen N-T & Lo SH 2009 Conditional loss of PTEN leads to skeletal abnormalities and lipoma formation. Molecular Carcinogenesis 48 545-552.
25. Kawai M, Breggia AC, DeMambro VE, Shen X, Canalis E, Bouxsein ML, Beamer WG, Clemmons DR & Rosen CJ 2011 The heparin-binding domain of IGFBP-2 has IGF binding-independent biologic activity in the growing skeleton. Journal of Biological Chemistry 286 14670-14680.
26. Kawamura N, Kugimiya F, Oshima Y, Ohba S, Ikeda T, Saito T, Shinoda Y, Kawasaki Y, Ogata N, Hoshi K et al. 2007 Akt1 in osteoblasts and osteoclasts controls bone remodeling. PLoS ONE 2 e1058.
27. Koga T, Matsui Y, AsagiriM, Kodama T, de Crombrugghe B, Nakashima K & Takayanagi H 2005 NFAT and Osterix cooperatively regulate bone formation. Nature Medicine 11 880-885.
28. Kousteni S 2011 FoxO1: a molecule for all seasons. Journal of Bone and Mineral Research 26 912-917.
29. Kronenberg HM 2003 Developmental regulation of the growth plate. Nature 423 332-336.
30. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY et al. 2007 Endocrine regulation of energy metabolism by the skeleton. Cell 130 456-469.
31. Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X &Wu H 2002 Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32 148-149.
32. Li L, Cserjesi P & Olson EN 1995 Dermo-1: a novel twist-related bHLH protein expressed in the developing dermis. Developmental Biology 172 280-292.
33. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R et al. 1997 PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 1943-1947.
34. Liu X, Bruxvoort KJ, Zylstra CR, Liu J, Cichowski R, Faugere M-C, Bouxsein ML, Wan C, Williams BO & Clemens TL 2007 Lifelong accumulation of bone in mice lacking Pten in osteoblasts. PNAS 104 2259-2264.
35. Maehama T & Dixon JE 1998 The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. Journal of Biological Chemistry 273 13375-13378.
36. Mandal C, Drissi H, Ghosh Choudhury G & Ghosh-Choudhury N 2010 Integration of phosphatidylinositol 3-kinase, Akt kinase, and Smad signaling pathway in BMP-2-induced Osterix expression. Calcified Tissue International 87 533-540.
37. Manning BD & Cantley LC 2007 AKT/PKB signaling: navigating downstream. Cell 129 1261-1274.
38. Moerman EJ, Teng K, Lipschitz DA & Lecka-Czemik B 2004 Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ2 transcription factor and TGF-β/ BMP signaling pathways. Aging Cell 3 379-389.
39. Mukherjee A, Wilson EM & Rotwein P 2010 Selective signaling by Akt2 promotes bone morphogenetic protein 2-mediated osteoblast differentiation. Molecular and Cellular Biology 30 1018-1027.
40. Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, Lindhout D, Cole WG, Henn W, Knoll JHM et al. 1997 Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 89 773-779.
41. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP & Tonks NK 1998 The lipid phosphatase activity of PTEN is critical for its tumor supressor function. PNAS 95 13513-13518.
42. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR & de Crombrugghe B 2002 The novel zinc finger-containing transcription factor Osterix is required for osteoblast differentiation and bone formation. Cell 108 17-29.
43. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK et al. 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine 344 1434-1441.
44. Nishio Y, Dong Y, Paris M, O'Keefe RJ, Schwarz EM & Drissi H 2006 Runx2-mediated regulation of the zinc finger Osterix/Sp7 gene. Gene 372 62-70.
45. Nuttall ME, Patton AJ, Olivera DL, Nadeau DP & Gowen M 1998 Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. Journal of Bone and Mineral Research 13 371-382.
46. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GWH, Beddington RSP, Mundlos S, Olsen BR et al. 1997 Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89 765-771.
47. Ovchinnikov DA, Deng JM, Ogunrinu G & Behringer RR 2000 Col2a1-directed expression of Cre recombinase in differentiating chondrocytes in transgenic mice. Genesis 26 145-146.
48. Pearman AT, Chou W-Y, Bergman KD, Pulumati MR & Partridge NC 1996 Parathyroid hormone induces c-fos promoter activity in osteoblastic cells through phosphorylated cAMP response element (CRE)-binding protein binding to the major CRE. Journal of Biological Chemistry 271 25715-25721.
49. Peng X-d, Xu P-Z, Chen M-L, Hahn-Windgassen A, Skeen J, Jacobs J, Sundararajan D, Chen WS, Crawford SE, Coleman KG et al. 2003 Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes and Development 17 1352-1365.
50. Phornphutkul C, Wu K-Y, Auyeung V, Chen Q & Gruppuso PA 2008 mTOR signaling contributes to chondrocyte differentiation. Developmental Dynamics 237 702-712.
51. Rached M-T, Kode A, Silva BC, Jung DY, Gray S, Ong H, Paik J-H, DePinho RA, Kim JK, Karsenty G et al. 2010a FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice. Journal of Clinical Investigation 120 357-368.
52. Rached M-T, Kode A, Xu L, Yoshikawa Y, Paik J-H, DePinho RA & Kousteni S 2010b FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts. Cell Metabolism 11 147-160.
53. Rokutanda S, Fujita T, Kanatani N, Yoshida CA, Komori H, Liu W, Mizuno A & Komori T 2009 Akt regulates skeletal development through GSK3, mTOR, and FoxOs. Developmental Biology 328 78-93.
54. Sanchez C & He Y-Z 2009 Bone growth during rapamycin therapy in young rats. BMC Pediatrics 9 3.
55. Sarbassov DD, Guertin DA, Ali SM & Sabatini DM 2005 Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 1098-1101.
56. Secreto FJ, Hoeppner LH &Westendorf JJ 2009 Wnt signaling during fracture repair. Current Osteoporosis Reports 7 64-69.
57. Singha UK, Jiang Y, Yu S, Luo M, Lu Y, Zhang J & Xiao G 2008 Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells. Journal of Cellular Biochemistry 103 434-446.
58. Suzuki A, YamaguchiMT, Ohteki T, Sasaki T, Kaisho T, Kimura Y, Yoshida R, Wakeham A, Higuchi T, Fukumoto M et al. 2001 T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14 523-534.
59. Ulici V, Hoenselaar KD, Agoston H, McErlain DD, Umoh J, Chakrabarti S, Holdsworth DW & Beier F 2009 The role of Akt1 in terminal stages of endochondral bone formation: angiogenesis and ossification. Bone 45 1133-1145.
60. Williams BO & Insogna KL 2009 Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone. Journal of Bone and Mineral Research 24 171-178.
61. Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T, Li L, Brancorsini S, Sassone-Corsi P, Townes TM et al. 2004 ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology: implication for Coffin-Lowry syndrome. Cell 117 387-398.
62. Yang G, Sun Q, Teng Y, Li F, Weng T & Yang X 2008 PTEN deficiency causes dyschondroplasia in mice by enhanced hypoxia-inducible factor 1α signaling and endoplasmic reticulum stress. Development 135 3587-3597.
63. Yang S, Xu H, Yu S, Cao H, Fan J, Ge C, Fransceschi RT, Dong HH & Xiao G 2011 FOXO1 mediates IGF1/insulin regulation of osteocalcin expression by antagonizing RUNX2 in osteoblasts. Journal of Biological Chemistry 286 19149-19158.
64. Yilmaz Ö H, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H & Morrison SJ 2006 Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 475-482.
65. Yoshizawa T, Hinoi E, Jung DY, Kajimura D, Ferron M, Seo J, Graff JM, Kim JK & Karsenty G 2009 The transcription factor ATF4 regulates glucose metabolism in mice through its expression in osteoblasts. Journal of Clinical Investigation 119 2807-2817.
66. Yu K, Xu J, Liu Z, Sosic D, Shao J, Olson EN, Towler DA & Ornitz DM 2003 Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development 130 3063-3074.
67. Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A et al. 2002 Osteoblastspecific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. Journal of Biological Chemistry 277 44005-44012.
68. Zhou X, Zhang Z, Feng JQ, Dusevich VM, Sinha K, Zhang H, Darnay BG & de Crombrugghe B 2010 Multiple functions of Osterix are required for bone growth and homeostasis in postnatal mice. PNAS 107 12919-12924.